What pterostilbene dose do studies use?
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Riche 2013 trial (University of Mississippi Medical Center) | 50 mg or 125 mg twice daily, against placebo and a 50 mg plus 100 mg grape extract arm1 | 80 adults with hypercholesterolemia, 20 per arm12 | 6 to 8 weeks1 |
| Otsuka 2025 pilot trial | 10 mg or 100 mg a day, against placebo3 | 30 healthy men3 | 12 weeks3 |
| City of Hope registry entry (NCT03671811, started 2019) | 100 mg twice daily by mouth, with 80 mg megestrol acetate twice daily, against megestrol acetate alone4 | 44 patients with endometrial cancer undergoing hysterectomy accrued, seven not evaluable4 | 3 weeks4 |
In a 2013 trial by Riche and colleagues in 80 adults with hypercholesterolemia, pterostilbene alone was given at 50 or 125 mg twice daily for 6 to 8 weeks against placebo, and a 2025 pilot trial by Otsuka and colleagues in 30 healthy men used 10 or 100 mg a day for 12 weeks; searches found no label or regulator dose.123
Trials of pterostilbene without nicotinamide riboside
The table is set at the top of the page
From that trial in adults with hypercholesterolemia over 6 to 8 weeks, Riche and colleagues concluded that pterostilbene is generally safe for use in humans up to 250 mg/day.1 DailyMed returned no pterostilbene label, and searches turned up no regulator dose. Searches returned no quotable list of capsule or tablet strengths sold; the one capsule strength found is from the Dellinger 2017 NRPT trial of 120 adults, whose product held 125 mg of nicotinamide riboside and 25 mg of pterostilbene per capsule.5 No Milligram logged figures for pterostilbene are shown, as none reached the reporting floor.
Doses with nicotinamide riboside
| Trial | Pterostilbene dose and schedule | People | Length |
|---|---|---|---|
| Dellinger 2017 NRPT trial | 50 or 100 mg a day, with 250 or 500 mg nicotinamide riboside, against placebo5 | 120 healthy adults aged 60 to 80, 40 per arm5 | eight weeks5 |
| Jensen 2022 trial (Aarhus) | 200 mg pterostilbene with 1,000 mg nicotinamide riboside daily, against placebo6; the registry entry gives NR/PT (500/100 mg twice daily)7 | Thirty-two people aged 55 to 806 | 45 days (registry entry)7 |
| Simic 2020 kidney-injury trial | Four steps, 250/50 to 1,000/200 mg of NR/PT, twice a day, with 5 people on NRPT and 1 on placebo per step8 | 24 hospitalized patients with acute kidney injury8 | 2 days per step8 |
The NO-ALS registry entry, listing 380 people with ALS, gives newly diagnosed patients a high-dose arm of 1500 mg nicotinamide riboside with 300 mg pterostilbene, a single-dose arm of 1000 mg with 200 mg, or placebo, and gives earlier diagnosed patients the high dose or placebo.9
Schedule, food, cycles and absorption
In the Riche 2013 trial of 80 adults, pterostilbene was taken by mouth twice daily, and the registry entry says the placebo was taken either one hour before or two hours after a meal.1012 A review says administering pterostilbene after a meal was observed to increase its oral absorption.11 In the Dellinger 2017 NRPT trial of 120 adults, each subject took their assigned treatment by mouth at breakfast, daily for 8 weeks.5 Searches returned no label schedule or cycle length for pterostilbene, and none of the trials states cycles; the trials gave it daily or twice daily for set periods.15
The BIOPTERO registry entry, a crossover study started in 2022 in 6 healthy volunteers, says the water solubility and bioavailability of pterostilbene are low, and compares a cocrystal form with the free form.12
Compared with resveratrol
Searches returned no human head-to-head comparison of pterostilbene and resveratrol doses. A review reports a rat study in which equal molar amounts gave pterostilbene higher exposure, which is animal data and not a human dose.11 The same review notes resveratrol has relatively poor oral bioavailability, while methylated polyphenols such as pterostilbene have better intestinal absorption.11
Storage, mixing and what is not known
Searches of DailyMed, PubMed and trial records returned no storage conditions or stability data for pterostilbene. The human studies in those searches used oral capsules or tablets, with no mixing instruction or liquid concentration.
Frequently asked questions
What is the most pterostilbene given in a day in a trial?
The highest found was in the Simic 2020 kidney-injury trial of 24 hospitalized patients, where 5 patients in the top step took NRPT with 1,000 mg nicotinamide riboside and 200 mg pterostilbene twice a day for 2 days, and its authors concluded NRPT up to a dose of 1000 mg/200 mg twice a day for 2 days was safe and well tolerated in these patients; without nicotinamide riboside, the highest was 125 mg twice daily in the Riche 2013 trial of 80 adults.812
Does pterostilbene have EU novel-food approval?
A 2021 toxicology review says stilbenes need a toxicological evaluation by EFSA before commercial use in food, and the EFSA novel-food approval it names is for trans-resveratrol; searches found no EU decision on pterostilbene, and the EU list of novel foods could not be fetched.13
How long have trials of pterostilbene run?
References
- Journal article (PMC). Analysis of Safety from a Human Clinical Trial with Pterostilbene. 2013. pmc.ncbi.nlm.nih.gov
- Journal article (PMC). Pterostilbene on Metabolic Parameters: A Randomized, Double-Blind, and Placebo-Controlled Trial. 2014. pmc.ncbi.nlm.nih.gov
- PubMed. Analysis of the Effects of Short-Term Pterostilbene Intake on Healthy Participants: A Pilot Study. 2025. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT03671811: Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy. 2026. clinicaltrials.gov
- Journal article (PMC). Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. 2017. pmc.ncbi.nlm.nih.gov
- Journal article (PMC). A randomized placebo-controlled trial of nicotinamide riboside and pterostilbene supplementation in experimental muscle injury in elderly individuals. 2022. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT03754842: Effect of Nicotinamide Riboside and Pterostilbene Supplementation on Muscle Regeneration in Elderly Humans. 2020. clinicaltrials.gov
- Journal article (PMC). Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI. 2020. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT04562831: The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS. 2027. clinicaltrials.gov
- ClinicalTrials.gov. NCT01267227: Effect of Pterostilbene on Cholesterol, Blood Pressure and Oxidative Stress. 2013. clinicaltrials.gov
- Journal article (PMC). New Insights into Dietary Pterostilbene: Sources, Metabolism, and Health Promotion Effects. 2022. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT05561075: Oral Bioavailability of Pterostilbene Cocrystal Compared to Its Free Form (BIOPTERO). 2022. clinicaltrials.gov
- Journal article (PMC). Toxicological Evaluation of Piceatannol, Pterostilbene, and ε-Viniferin for Their Potential Use in the Food Industry: A Review. 2021. pmc.ncbi.nlm.nih.gov
- PubMed. Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial. 2023. pubmed.ncbi.nlm.nih.gov